2788 Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 

CALENDAR OF REPORTING DATES FOR CALIFORNIA SPECIAL ELECTIONS

Report Close of books 1

Reg./cert. & 

overnight mailing 

deadline 

Filing deadline 

If Only the Special General (04/05/2022) Is Held, Committees Involved Must File 

Pre-General ............................................................................................................... 03/16/2022 03/21/2022 03/24/2022 

April Quarterly ............................................................................................................ 03/31/2022 04/15/2022 04/15/2022 

Post-General .............................................................................................................. 04/25/2022 05/05/2022 05/05/2022 

July Quarterly ............................................................................................................. 06/30/2022 07/15/2022 07/15/2022 

If Two Elections Are Held, Committees Involved in Only the Special General (04/05/2022) Must File 

Pre-General ............................................................................................................... 03/16/2022 03/21/2022 03/24/2022 

April Quarterly ............................................................................................................ 03/31/2022 04/15/2022 04/15/2022 

Committees Involved in Both the Special General (04/05/2022) and Special Runoff (06/07/2022) Must File 

Pre-General ............................................................................................................... 03/16/2022 03/21/2022 03/24/2022 

April Quarterly ............................................................................................................ 03/31/2022 04/15/2022 04/15/2022 

Pre-Runoff .................................................................................................................. 05/18/2022 05/23/2022 05/26/2022 

Post-Runoff ................................................................................................................ 06/27/2022 07/07/2022 07/07/2022 

July Quarterly ............................................................................................................. —- WAIVED —- 

October Quarterly ...................................................................................................... 09/30/2022 10/15/2022 2 10/15/2022 

Committees Involved In Only the Special Runoff (06/07/2022) Must File 

Pre-Runoff .................................................................................................................. 05/18/2022 05/23/2022 05/26/2022 

Post-Runoff ................................................................................................................ 06/27/2022 07/07/2022 07/07/2022 

July Quarterly ............................................................................................................. — WAIVED — 

October Quarterly ...................................................................................................... 09/30/2022 10/15/2022 2 10/15/2022 

1The reporting period always begins the day after the closing date of the last report filed. If the committee is new and has not previously filed 

a report, the first report must cover all activity that occurred before the committee registered as a political committee up through the close of 

books for the first report due. 2 Notice that this filing deadline falls on a weekend or federal holiday. Filing deadlines are not extended when they fall on nonworking days. 

Accordingly, reports filed by methods other than registered, certified or overnight mail, or electronically, must be received before the Commission’s close of business on the last business day before the deadline. 

Dated: January 12, 2022. 

On behalf of the Commission. 

Allen J. Dickerson, 

Chairman, Federal Election Commission. 

[FR Doc. 2022–00945 Filed 1–18–22; 8:45 am] 

BILLING CODE 6715–01–P 

FEDERAL TRADE COMMISSION 

[File No. 172 3196] 

Dun & Bradstreet, Inc.; Analysis of 

Proposed Consent Order to Aid Public 

Comment 

AGENCY: Federal Trade Commission. 

ACTION: Proposed consent agreement; 

request for comment. 

SUMMARY: The consent agreement in this 

matter settles alleged violations of 

federal law prohibiting unfair or 

deceptive acts or practices. The attached 

Analysis of Proposed Consent Order to 

Aid Public Comment describes both the 

allegations in the draft complaint and 

the terms of the consent order— 

embodied in the consent agreement— 

that would settle these allegations. 

DATES: Comments must be received on 

or before February 18, 2022. 

ADDRESSES: Interested parties may file 

comments online or on paper by 

following the instructions in the 

Request for Comment part of the 

SUPPLEMENTARY INFORMATION section 

below. Please write ‘‘Dun & Bradstreet, 

Inc.; File No. 172 3196’’ on your 

comment and file your comment online 

at https://www.regulations.gov by 

following the instructions on the webbased form. If you prefer to file your 

comment on paper, mail your comment 

to the following address: Federal Trade 

Commission, Office of the Secretary, 

600 Pennsylvania Avenue NW, Suite 

CC–5610 (Annex D), Washington, DC 

20580, or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW, 

5th Floor, Suite 5610 (Annex D), 

Washington, DC 20024. 

FOR FURTHER INFORMATION CONTACT: 

Dana C. Barragate, Attorney (216–263– 

3402), Federal Trade Commission, East 

Central Region, 1111 Superior Avenue, 

Suite 200, Cleveland, OH 44114–2507. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 6(f) of the Federal Trade 

Commission Act, 15 U.S.C. 46(f), and 

FTC Rule 2.34, 16 CFR 2.34, notice is 

hereby given that the above-captioned 

consent agreement containing a consent 

order to cease and desist, having been 

filed with and accepted, subject to final 

approval, by the Commission, has been 

placed on the public record for a period 

of thirty (30) days. The following 

Analysis to Aid Public Comment 

describes the terms of the consent 

agreement and the allegations in the 

complaint. An electronic copy of the 

full text of the consent agreement 

package can be obtained at https://

www.ftc.gov/news-events/commissionactions. 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before February 18, 2022. Write ‘‘Dun & 

Bradstreet, Inc.; File No. 172 3196’’ on 

your comment. Your comment— 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 2789 

including your name and your state— 

will be placed on the public record of 

this proceeding, including, to the extent 

practicable, on the https://

www.regulations.gov website. 

Due to the COVID–19 pandemic and 

the agency’s heightened security 

screening, postal mail addressed to the 

Commission will be subject to delay. We 

strongly encourage you to submit your 

comments online through the https://

www.regulations.gov website. 

If you prefer to file your comment on 

paper, write ‘‘Dun & Bradstreet, Inc.; 

File No. 172 3196’’ on your comment 

and on the envelope, and mail your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, 600 Pennsylvania Avenue 

NW, Suite CC–5610 (Annex D), 

Washington, DC 20580; or deliver your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, Constitution Center, 400 7th 

Street SW, 5th Floor, Suite 5610 (Annex 

D), Washington, DC 20024. If possible, 

submit your paper comment to the 

Commission by courier or overnight 

service. 

Because your comment will be placed 

on the publicly accessible website at 

https://www.regulations.gov, you are 

solely responsible for making sure your 

comment does not include any sensitive 

or confidential information. Your 

comment should not include sensitive 

personal information, such as your or 

anyone else’s Social Security number; 

date of birth; driver’s license number or 

other state identification number, or 

foreign country equivalent; passport 

number; financial account number; or 

credit or debit card number. You are 

also solely responsible for making sure 

your comment does not include 

sensitive health information, such as 

medical records or other individually 

identifiable health information. In 

addition, your comment should not 

include any ‘‘trade secret or any 

commercial or financial information 

which . . . is privileged or 

confidential’’—as provided by Section 

6(f) of the FTC Act, 15 U.S.C. 46(f), and 

FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— 

including competitively sensitive 

information such as costs, sales 

statistics, inventories, formulas, 

patterns, devices, manufacturing 

processes, or customer names. 

Comments containing material for 

which confidential treatment is 

requested must be filed in paper form, 

must be clearly labeled ‘‘Confidential,’’ 

and must comply with FTC Rule 4.9(c). 

In particular, the written request for 

confidential treatment that accompanies 

the comment must include the factual 

and legal basis for the request, and must 

identify the specific portions of the 

comment to be withheld from the public 

record. See FTC Rule 4.9(c). Your 

comment will be kept confidential only 

if the General Counsel grants your 

request in accordance with the law and 

the public interest. Once your comment 

has been posted on the https://

www.regulations.gov website—as legally 

required by FTC Rule 4.9(b)—we cannot 

redact or remove your comment from 

that website, unless you submit a 

confidentiality request that meets the 

requirements for such treatment under 

FTC Rule 4.9(c), and the General 

Counsel grants that request. 

Visit the FTC website at http://

www.ftc.gov to read this Notice and the 

news release describing the proposed 

settlement. The FTC Act and other laws 

that the Commission administers permit 

the collection of public comments to 

consider and use in this proceeding, as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before February 18, 2022. For 

information on the Commission’s 

privacy policy, including routine uses 

permitted by the Privacy Act, see 

https://www.ftc.gov/site-information/ 

privacy-policy. 

Analysis of Proposed Consent Order To 

Aid Public Comment 

The Federal Trade Commission 

(‘‘FTC’’ or ‘‘Commission’’) has accepted, 

subject to final approval, an agreement 

containing a proposed consent order 

(‘‘Proposed Order’’) from Dun & 

Bradstreet, Inc. (‘‘D&B’’). The Proposed 

Order has been placed on the public 

record for 30 days to receive comments 

by interested persons. Comments 

received during this period will become 

part of the public record. After 30 days, 

the Commission will again review the 

agreement and the comments received 

and will decide whether it should 

withdraw from the agreement and take 

appropriate action or make final the 

agreement’s Proposed Order. 

This matter involves D&B’s sale of 

paid CreditBuilder and related products 

(‘‘CreditBuilder products’’). D&B 

typically marketed CreditBuilder 

products to small and mid-sized 

businesses (who are the consumers in 

this matter) as a means to improve what 

D&B reports about the business on its 

commercial credit reports. The FTC’s 

proposed five-count complaint 

challenges several of D&B’s 

CreditBuilder sales and renewal 

practices as deceptive, and also alleges 

that certain conduct was unfair, all in 

violation of Section 5(a) of the Federal 

Trade Commission Act (‘‘FTC Act’’), 15 

U.S.C. 45(a). 

The first four counts of the proposed 

complaint allege deceptive acts or 

practices in violation of the FTC Act. 

• First, the complaint alleges D&B’s 

representations that a business could 

use CreditBuilder products to have 

previously unreported commercial 

payment experiences added to its credit 

report, and that D&B would actively 

assist CreditBuilder customers in adding 

payment experiences, were deceptive 

because, in numerous instances, 

customers did not get payment 

experiences added, and D&B did not 

actively assist the customer in adding 

payment experiences. 

• Second, the complaint alleges D&B 

made false claims that CreditBuilder 

products were required for D&B to 

conduct a background check on the 

business or to complete its D&B report, 

including providing the business with a 

full set of scores and ratings. 

• Third, the complaint alleges that, in 

connection with collecting updated 

payment information for CreditBuilder 

products scheduled to renew, D&B 

sometimes misrepresented that D&B was 

collecting payment for and renewing the 

product that the business purchased the 

prior term, when, in fact, D&B was 

collecting payment information to enroll 

the customer in a different product from 

the one to which the customer 

previously subscribed. 

• Fourth, the complaint alleges that 

when D&B collected customer credit 

card information for payment, it failed 

to adequately disclose practices that 

resulted in recurring and increasing 

charges, including automatic billing. 

In addition to the alleged deceptive 

marketing and renewal practices, the 

complaint alleges in its fifth count that 

D&B engaged in an unfair practice by 

reporting incorrect information on 

businesses’ credit reports while failing 

to provide those businesses with a 

reasonable means to dispute such 

information and have inaccurate 

information corrected. The proposed 

complaint alleges this conduct caused 

or is likely to cause substantial injury to 

consumers that is not outweighed by 

countervailing benefits to consumers or 

competition and is not reasonably 

avoided by consumers themselves. Such 

practice constitutes an unfair act or 

practice in violation of Section 5 of the 

FTC Act. 

The Proposed Order is designed to 

prevent D&B from engaging in similar 

acts or practices in the future. It 

includes injunctive relief to address 

these alleged violations. 

• Part I prohibits future deceptive 

acts and practices similar to those at 

issue in the complaint by prohibiting 

D&B from misrepresenting: 


jspears on DSK121TN23PROD with NOTICES1
2790 Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 

Æ That using D&B’s product is likely 

to allow a business to have its 

previously unreported commercial 

payment experiences added to its credit 

report; 

Æ That D&B will actively assist a 

business in adding its unreported 

commercial payment experiences to its 

credit report; 

Æ That using D&B’s product is likely 

to help a business build or improve its 

credit report; 

Æ The ease with which information or 

payment experiences can be added to a 

business’s credit report; and 

Æ That D&B’s product is needed when 

it is not, and that a product will enable 

a prospective customer to have a 

‘‘complete’’ file. 

• Part I also features ancillary relief 

relating to the challenged conduct by 

prohibiting misrepresentations relating 

to what payment experiences customers 

can add, as well as to D&B’s renewal 

and charging practices. 

• Part II provides additional specific 

relief relating to D&B’s renewal and 

charging practices for products covered 

under the Proposed Order, to make sure 

that D&B makes clear disclosures about 

renewals both before a customer 

subscribes and during the period of the 

subscription. 

• Parts III and IV require D&B to make 

certain disclosures to potential 

customers of CreditBuilder products, so 

that those potential customers can make 

better informed decisions about whether 

to purchase the products. 

• Part V sets out specific 

requirements for D&B to follow when a 

business disputes information that D&B 

reports about it. The requirements of 

this Part V apply generally and are not 

limited only to D&B customers. 

• Part VI requires D&B to offer 

refunds (or partial refunds) to certain 

customers and former customers of 

CreditBuilder products. Refund or 

partial refund eligibility under the 

Proposed Order will depend on 

customers’ specific circumstances and 

how they used or attempted to use their 

CreditBuilder products. 

• Part VII requires D&B to send 

notices to all current customers of paid 

products covered under the Proposed 

Order that automatically renew. 

Parts VIII through XII are reporting 

and compliance provisions. Part VIII 

mandates that D&B acknowledge receipt 

of the Proposed Order and, for three 

years, distribute the Proposed Order to 

certain employees and agents and 

secure acknowledgments from 

recipients of the Proposed Order. Part IX 

requires D&B to submit compliance 

reports to the FTC one year after the 

order’s issuance and submit additional 

reports when certain events occur. Part 

X requires that, for 10 years, D&B 

creates certain records and retain them 

for at least 5 years. Part XI provides for 

the FTC’s continued compliance 

monitoring of D&B’s activity during the 

Proposed Order’s effective dates. Part 

XII is a provision ‘‘sunsetting’’ the 

Proposed Order after 20 years, with 

certain exceptions. 

The purpose of this analysis is to 

facilitate public comment on the 

Proposed Order. It is not intended to 

constitute an official interpretation of 

the complaint or Proposed Order, or to 

modify in any way the Proposed Order’s 

terms. 

By direction of the Commission. 

April J. Tabor, 

Secretary. 

[FR Doc. 2022–00938 Filed 1–18–22; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Patient Safety Organizations: 

Voluntary Relinquishment for the 

Theator, Inc. PSO 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of delisting. 

SUMMARY: The Patient Safety and 

Quality Improvement Final Rule 

(Patient Safety Rule) authorizes AHRQ, 

on behalf of the Secretary of HHS, to list 

as a patient safety organization (PSO) an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ by 

the Secretary if it is found to no longer 

meet the requirements of the Patient 

Safety and Quality Improvement Act of 

2005 (Patient Safety Act) and Patient 

Safety Rule, when a PSO chooses to 

voluntarily relinquish its status as a 

PSO for any reason, or when a PSO’s 

listing expires. AHRQ accepted a 

notification of proposed voluntary 

relinquishment from the Theator, Inc. 

PSO, PSO number P0218, of its status as 

a PSO, and has delisted the PSO 

accordingly. 

DATES: The delisting was effective at 

12:00 Midnight ET (2400) on December 

22, 2021. 

ADDRESSES: The directories for both 

listed and delisted PSOs are ongoing 

and reviewed weekly by AHRQ. Both 

directories can be accessed 

electronically at the following HHS 

website: http://www.pso.ahrq.gov/listed. 

FOR FURTHER INFORMATION CONTACT: 

Cathryn Bach, Center for Quality 

Improvement and Patient Safety, AHRQ, 

5600 Fishers Lane, MS 06N100B, 

Rockville, MD 20857; Telephone (toll 

free): (866) 403–3697; Telephone (local): 

(301) 427–1111; TTY (toll free): (866) 

438–7231; TTY (local): (301) 427–1130; 

Email: pso@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Patient Safety Act, 42 U.S.C. 

299b–21 to 299b–26, and the related 

Patient Safety Rule, 42 CFR part 3, 

published in the Federal Register on 

November 21, 2008 (73 FR 70732– 

70814), establish a framework by which 

individuals and entities that meet the 

definition of provider in the Patient 

Safety Rule may voluntarily report 

information to PSOs listed by AHRQ, on 

a privileged and confidential basis, for 

the aggregation and analysis of patient 

safety work product. 

The Patient Safety Act authorizes the 

listing of PSOs, which are entities or 

component organizations whose 

mission and primary activity are to 

conduct activities to improve patient 

safety and the quality of health care 

delivery. 

HHS issued the Patient Safety Rule to 

implement the Patient Safety Act. 

AHRQ administers the provisions of the 

Patient Safety Act and Patient Safety 

Rule relating to the listing and operation 

of PSOs. The Patient Safety Rule 

authorizes AHRQ to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ if 

it is found to no longer meet the 

requirements of the Patient Safety Act 

and Patient Safety Rule, when a PSO 

chooses to voluntarily relinquish its 

status as a PSO for any reason, or when 

a PSO’s listing expires. Section 3.108(d) 

of the Patient Safety Rule requires 

AHRQ to provide public notice when it 

removes an organization from the list of 

PSOs. 

AHRQ has accepted a notification of 

proposed voluntary relinquishment 

from the Theator, Inc. PSO to 

voluntarily relinquish its status as a 

PSO. Accordingly, the Theator, Inc. 

PSO, P0218, was delisted effective at 

12:00 Midnight ET (2400) on December 

22, 2021. 

More information on PSOs can be 

obtained through AHRQ’s PSO website 

at http://www.pso.ahrq.gov. 


jspears on DSK121TN23PROD with NOTICES1